MedTrace Logo

Study to Assess the Safety and Tolerability of PBF-1650 in Healthy Volunteers.

NCT03798236 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2020-06-30

No results posted yet for this study

Summary

Single center, randomized, double-blind, placebo-controlled clinical study to assess the safety and tolerability of PBF-1650 in order to obtain the Maximum Tolerated Dose (MTD).

Conditions

Interventions

DRUG

PBF-1650 oral capsules

Adenosine A3 receptor (AA3R) antagonist

DRUG

Placebo oral capsule

solid microcrystalline cellulose

Sponsors & Collaborators

  • Clínica Universidad de Navarra

    collaborator UNKNOWN

  • Palobiofarma SL

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-12-10
Primary Completion
2019-03-30
Completion
2019-05-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03798236 on ClinicalTrials.gov